Click here to close now.




















Welcome!

News Feed Item

Historical Income Statements Recast for DERMAGRAFT Discontinued Operations

DUBLIN, February 4, 2014 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today releases historical income statements on both a US GAAP and Non GAAP basis for 2012 and the nine months ended September 30, 2013, recast to show the impact of DERMAGRAFT operations as discontinued.

On January 17, 2014 Shire announced that it had entered into a definitive agreement pursuant to which it has sold certain of its DERMAGRAFT assets to Organogenesis Inc. comprising the key operating assets relating to development, manufacture and sale of DERMAGRAFT product. From the agreement date Organogenesis Inc. assumed all further financial and management responsibility for DERMAGRAFT.

As a result of this divestment DERMAGRAFT operations will be presented as discontinued operations, net of tax, in Shire's fourth quarter and 2013 full year Earnings Release. Shire will also provide in its Earnings Release, as a memo, Non GAAP financial information including DERMAGRAFT, which management believes will be useful to investors for comparing total company performance against guidance previously issued by Shire. The format of this memo information can be found on pages 9 and 10 of this release.

Shire's historical statements of operations for all periods in 2013, 2012 and 2011 will also be adjusted to present DERMAGRAFT operations as discontinued.

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.

FORWARD - LOOKING STATEMENTS - "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included in this announcement that are not historical facts are forward-looking statements. Forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, that:

  • Shire's products may not be a commercial success;
  • revenues from ADDERALL XR are subject to generic erosion;
  • the failure to obtain and maintain reimbursement, or an adequate level of reimbursement, by third-party payors in a timely manner for Shire's products may impact future revenues and earnings;
  • Shire relies on a single source for manufacture of certain of its products and a disruption to the supply chain for those products may result in Shire being unable to continue marketing or developing a product or may result in Shire being unable to do so on a commercially viable basis;
  • Shire uses third party manufacturers to manufacture many of its products and is reliant upon third party contractors for certain goods and services, and any inability of these third party manufacturers to manufacture products, or any failure of these third party contractors to provide these goods and services, in each case in accordance with its respective contractual obligations, could adversely affect Shire's ability to manage its manufacturing processes or to operate its business;
  • the development, approval and manufacturing of Shire's products is subject to extensive oversight by various regulatory agencies and regulatory approvals or interventions associated with changes to manufacturing sites, ingredients or manufacturing processes could lead to significant delays, increase in operating costs, lost product sales, an interruption of research activities or the delay of new product launches;
  • the actions of certain customers could affect Shire's ability to sell or market products profitably and fluctuations in buying or distribution patterns by such customers could adversely impact Shire's revenues, financial conditions or results of operations;
  • investigations or enforcement action by regulatory authorities or law enforcement agencies relating to Shire's activities in the highly regulated markets in which it operates may result in the distraction of senior management, significant legal costs and the payment of substantial compensation or fines;
  • adverse outcomes in legal matters and other disputes, including Shire's ability to obtain, maintain, enforce and defend patents and other intellectual property rights required for its business, could have a material adverse effect on Shire's revenues, financial condition or results of operations;
  • failure to achieve Shire's strategic objectives with respect to the acquisition of ViroPharma Incorporated, may adversely affect Shire's financial condition and results of operations;

and other risks and uncertainties detailed from time to time in Shire's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K.


Unaudited US GAAP results for the nine months to September 30, 2013 recast for DERMAGRAFT as a discontinued operation

                                       Recast  Recast  Recast     Recast
                                                                 Sep YTD
                                      Q1 2013 Q2 2013 Q3 2013       2013
                                          $'M     $'M     $'M        $'M

    Revenues:                         ___________ ___________ ___________ ___________
    Product sales                     1,098.2 1,207.9 1,171.0    3,477.1
    Royalties                            38.5    36.3    37.6      112.4
    Other revenues                        6.7     8.0     4.1       18.8

                                      ___________ ___________ ___________ ___________
    Total revenues                    1,143.4 1,252.2 1,212.7    3,608.3

                                      ___________ ___________ ___________ ___________
    Costs and expenses:
    Cost of product sales               147.4   164.3   180.5      492.2
    Research and development            220.6   256.5   226.2      703.3
    Selling, general and
    administrative                      391.7   410.0   396.3    1,198.0
    Goodwill impairment charge            7.1       -       -        7.1
    Gain on sale of product rights      (6.5)   (4.5)   (3.6)     (14.6)
    Reorganization costs                 17.5    17.7    12.0       47.2
    Integration and acquisition costs     4.1    17.4    18.4       39.9

                                      ___________ ___________ ___________ ___________
    Total operating expenses            781.9   861.4   829.8    2,473.1

                                      ___________ ___________ ___________ ___________

    Operating income                    361.5   390.8   382.9    1,135.2

    Interest income                       0.7     0.5     0.4        1.6
    Interest expense                    (9.2)   (9.1)   (9.2)     (27.5)
    Other (expense)/income, net         (1.0)   (1.3)     0.7      (1.6)

                                      ___________ ___________ ___________ ___________
    Total other expense, net            (9.5)   (9.9)   (8.1)     (27.5)

                                      ___________ ___________ ___________ ___________
    Income from continuing operations
    before income taxes and equity in
    earnings/(losses) of equity
    method investees                    352.0   380.9   374.8    1,107.7
    Income taxes                       (71.4)  (90.5)  (73.4)    (235.3)
    Equity in earnings/(losses) of
    equity method investees, net of
    tax                                   0.4     0.5   (0.3)        0.6

                                      ___________ ___________ ___________ ___________
    Income from continuing operations   281.0   290.9   301.1      873.0
    Loss from discontinued operations (216.2)  (32.8)  (22.9)    (271.9)

                                      ___________ ___________ ___________ ___________
    Net Income                           64.8   258.1   278.2      601.1

                                      ___________ ___________ ___________ ___________
    Impact of convertible debt, net
    of tax                                7.6     7.5     7.6       22.7

    Numerator for diluted EPS            72.4   265.6   285.8      623.8

                                      ___________ ___________ ___________ ___________
    Weighted average number of share
    (millions) - diluted                588.9   586.0   585.7      587.5

    Diluted earnings per ADS            36.9c  135.9c  146.4c     318.6c

                                      ___________ ___________ ___________ ___________



Unaudited Non GAAP results for the nine months to September 30, 2013 recast for DERMAGRAFT as a discontinued operation

                                  Recast  Recast  Recast     Recast
                                                            Sep YTD
                                 Q1 2013 Q2 2013 Q3 2013       2013
                                     $'M     $'M     $'M        $'M

    Revenues:                    ___________ ___________ ___________ ___________
    Product sales                1,098.2 1,207.9 1,171.0    3,477.1
    Royalties                       38.5    36.3    37.6      112.4
    Other revenues                   6.7     8.0     4.1       18.8

                                 ___________ ___________ ___________ ___________
    Total revenues               1,143.4 1,252.2 1,212.7    3,608.3

                                 ___________ ___________ ___________ ___________
    Costs and expenses:
    Cost of product sales          140.3   155.1   170.3      465.7
    Research and development       216.0   232.3   219.9      668.2
    Selling, general and
    administrative                 337.9   356.7   341.2    1,035.8
    Depreciation                    27.8    29.1    32.4       89.3

                                 ___________ ___________ ___________ ___________
    Total operating expenses       722.0   773.2   763.8    2,259.0

                                 ___________ ___________ ___________ ___________

    Operating income               421.4   479.0   448.9    1,349.3

    Interest income                  0.7     0.5     0.4        1.6
    Interest expense               (9.2)   (9.1)   (9.2)     (27.5)
    Other (expense)/income, net    (1.0)   (1.3)     0.7      (1.6)

                                 ___________ ___________ ___________ ___________
    Total other expense, net       (9.5)   (9.9)   (8.1)     (27.5)

                                 ___________ ___________ ___________ ___________
    Income from continuing
    operations before income
    taxes and equity in
    earnings/(losses) of equity
    method investees               411.9   469.1   440.8    1,321.8
    Income taxes                  (83.5) (109.5)  (90.3)    (283.3)
    Equity in earnings/(losses)
    of equity method investees,
    net of tax                       0.4     0.5   (0.3)        0.6

                                 ___________ ___________ ___________ ___________
    Net Income                     328.8   360.1   350.2    1,039.1

                                 ___________ ___________ ___________ ___________
    Impact of convertible debt,
    net of tax                       7.6     7.5     7.6       22.7

    Numerator for diluted EPS      336.4   367.6   357.8    1,061.8

                                 ___________ ___________ ___________ ___________
    Weighted average number of
    share (millions) - diluted     588.9   586.0   585.7      587.5

    Diluted earnings per ADS      171.6c  188.1c  183.3c     542.1c

                                 ___________ ___________ ___________ ___________
    Memo:
    Previously reported Non GAAP
    EPS per ADS (prior to
    treatment of DERMAGRAFT
    operation as a discontinued
    operation)                    162.9c  178.8c  176.7c     517.5c



Unaudited Non GAAP results for the nine months to September 30, 2013 for the DERMAGRAFT discontinued operations

The table below shows the 2013 loss related to DERMAGRAFT operations that has been reclassified to discontinued operations:

                                                                 Q2     Q3 Sep YTD
                                                     Q1 2013   2013   2013    2013
                                                         $'M    $'M    $'M     $'M

                                                     ___________ ___________ ___________
    Total revenues                                      18.5   22.3   23.9    64.7

                                                     ___________ ___________ ___________
    Cost of product sales                                7.8   10.6   15.8    34.2
    Research and development                             3.6    3.6    2.9    10.1
    Selling, general and administrative                 34.0   33.7   30.5    98.2
    Depreciation                                         1.3    1.3    1.4     4.0

                                                     ___________ ___________ ___________
    Total operating expenses                            46.7   49.2   50.6   146.5
    Total other income, net                                -    0.1    0.1     0.2

                                                     ___________ ___________ ___________
    Loss from discontinued operations before income
    taxes                                             (28.2) (26.8) (26.6)  (81.6)
    Income taxes                                        11.7    8.2   13.6    33.5

                                                     ___________ ___________ ___________
    Non GAAP net loss from discontinued operations    (16.5) (18.6) (13.0)  (48.1)

                                                     ___________ ___________ ___________
    Amortization and asset impairments, net of taxes (198.0)  (6.3)  (6.3) (210.6)
    Divestments, reorganizations and discontinued
    operations, net of taxes                               -  (5.6)  (1.1)   (6.7)
    Legal and litigation costs, net of taxes           (1.7)  (2.3)  (2.5)   (6.5)

                                                     ___________ ___________ ___________
    US GAAP net loss from discontinued operations    (216.2) (32.8) (22.9) (271.9)

                                                     ___________ ___________ ___________


Unaudited US GAAP results for 2012 recast for DERMAGRAFT as a discontinued operation

                                       Recast  Recast  Recast  Recast  Recast
                                      Q1 2012 Q2 2012 Q3 2012 Q4 2012 FY 2012
                                          $'M     $'M     $'M     $'M     $'M

    Revenues:                         ___________ ___________ ___________ ___________
    Product sales                     1,058.1 1,095.3 1,020.8 1,078.7 4,252.9
    Royalties                            56.3    56.3    41.8    87.2   241.6
    Other revenues                        8.6     3.8     4.1    16.4    32.9

                                      ___________ ___________ ___________ ___________
    Total revenues                    1,123.0 1,155.4 1,066.7 1,182.3 4,527.4

                                      ___________ ___________ ___________ ___________
    Costs and expenses:
    Cost of product sales               148.4   135.5   151.9   150.0   585.8
    Research and development            217.3   235.8   221.0   278.9   953.0
    Selling, general and
    administrative                      458.1   467.7   396.9   625.3 1,948.0
    Gain on sale of product rights      (7.2)   (3.6)   (5.7)   (1.6)  (18.1)
    Integration and acquisition costs     1.5     3.1     1.5     7.4    13.5

                                      ___________ ___________ ___________ ___________
    Total operating expenses            818.1   838.5   765.6 1,060.0 3,482.2

                                      ___________ ___________ ___________ ___________

    Operating income                    304.9   316.9   301.1   122.3 1,045.2

    Interest income                       0.8     0.6     0.9     0.7     3.0
    Interest expense                   (10.2)   (9.6)   (9.2)   (9.2)  (38.2)
    Other income/(expense), net           1.9   (1.8)     3.5   (5.8)   (2.2)

                                      ___________ ___________ ___________ ___________
    Total other expense, net            (7.5)  (10.8)   (4.8)  (14.3)  (37.4)

                                      ___________ ___________ ___________ ___________
    Income from continuing operations
    before income taxes and equity in
    earnings/(losses) of equity
    method investees                    297.4   306.1   296.3   108.0 1,007.8
    Income taxes                       (52.5)  (57.0)  (53.1)  (40.5) (203.1)
    Equity in earnings/(losses) of
    equity method investees, net of
    tax                                   0.9   (0.6)     0.2     0.5     1.0

                                      ___________ ___________ ___________ ___________
    Income from continuing operations   245.8   248.5   243.4    68.0   805.7
    Loss from discontinued operations   (7.4)  (10.7)  (16.2)  (26.0)  (60.3)

                                      ___________ ___________ ___________ ___________
    Net Income                          238.4   237.8   227.2    42.0   745.4

                                      ___________ ___________ ___________ ___________
    Impact of convertible debt, net
    of tax                                8.4     7.8     7.5       -    31.3

    Numerator for diluted EPS           246.8   245.6   234.7    42.0   776.7

                                      ___________ ___________ ___________ ___________
    Weighted average number of share
    (millions) - diluted                595.6   594.9   593.1   558.5   593.5

    Diluted earnings per ADS           124.2c  123.9c  118.8c   22.5c  392.7c

                                      ___________ ___________ ___________ ___________


Unaudited Non GAAP results for 2012 recast for DERMAGRAFT as a discontinued operation

                                  Recast  Recast  Recast  Recast  Recast
                                 Q1 2012 Q2 2012 Q3 2012 Q4 2012 FY 2012
                                     $'M     $'M     $'M     $'M     $'M

    Revenues:                    ___________ ___________ ___________ ___________
    Product sales                1,058.1 1,095.3 1,020.8 1,078.7 4,252.9
    Royalties                       56.3    56.3    41.8    87.2   241.6
    Other revenues                   8.6     3.8     4.1    16.4    32.9

                                 ___________ ___________ ___________ ___________
    Total revenues               1,123.0 1,155.4 1,066.7 1,182.3 4,527.4

                                 ___________ ___________ ___________ ___________
    Costs and expenses:
    Cost of product sales          141.8   129.1   143.2   142.7   556.8
    Research and development       187.9   202.4   215.5   230.5   836.3
    Selling, general and
    administrative                 409.4   380.3   341.5   384.9 1,516.1
    Depreciation                    25.9    26.7    27.9    28.5   109.0

                                 ___________ ___________ ___________ ___________
    Total operating expenses       765.0   738.5   728.1   786.6 3,018.2

                                 ___________ ___________ ___________ ___________

    Operating income               358.0   416.9   338.6   395.7 1,509.2

    Interest income                  0.8     0.6     0.9     0.7     3.0
    Interest expense              (10.2)   (9.6)   (9.2)   (9.2)  (38.2)
    Other income/(expense), net      1.9   (1.8)     3.5   (1.8)     1.8

                                 ___________ ___________ ___________ ___________
    Total other expense, net       (7.5)  (10.8)   (4.8)  (10.3)  (33.4)

                                 ___________ ___________ ___________ ___________
    Income from continuing
    operations before income
    taxes and equity in
    earnings/(losses) of equity
    method investees               350.5   406.1   333.8   385.4 1,475.8
    Income taxes                  (67.3)  (80.6)  (64.9)  (66.3) (279.1)
    Equity in earnings/(losses)
    of equity method investees,
    net of tax                       0.9   (0.6)     0.2     0.5     1.0

                                 ___________ ___________ ___________ ___________
    Net Income                     284.1   324.9   269.1   319.6 1,197.7

                                 ___________ ___________ ___________ ___________
    Impact of convertible debt,
    net of tax                       8.4     7.8     7.5     7.6    31.3

    Numerator for diluted EPS      292.5   332.7   276.6   327.2 1,229.0

                                 ___________ ___________ ___________ ___________
    Weighted average number of
    share (millions) - diluted     595.6   594.9   593.1   592.0   593.5

    Diluted earnings per ADS      147.3c  167.7c  139.8c  165.6c  621.0c

                                 ___________ ___________ ___________ ___________
    Memo:
    Previously reported Non GAAP
    EPS per ADS (prior to
    treatment of DERMAGRAFT
    operation as a discontinued
    operation)                    147.9c  168.0c  136.2c  157.8c  610.5c


Unaudited Non GAAP results for 2012 for the DERMAGRAFT discontinued operations

The table below shows the 2012 income/(loss) related to DERMAGRAFT operations that has been reclassified to discontinued operations:

                                                             Q1     Q2     Q3     Q4     FY
                                                           2012   2012   2012   2012   2012
                                                            $'M    $'M    $'M    $'M    $'M

                                                          ___________ ___________ _________
    Total revenues                                         48.8   52.4   33.7   18.9  153.8

                                                          ___________ ___________ _________
    Cost of product sales                                   9.4   16.4   15.3   16.0   57.1
    Research and development                                3.0    2.8    3.7    3.0   12.5
    Selling, general and administrative                    31.4   29.3   27.2   26.8  114.7
    Depreciation                                            1.3    1.2    1.2    1.1    4.8

                                                          ___________ ___________ _________
    Total operating expenses                               45.1   49.7   47.4   46.9  189.1
    Total other expense, net                                  -      -      -  (0.4)  (0.4)

                                                          ___________ ___________ _________
    Income/(loss) from discontinued operations before
    income taxes                                            3.7    2.7 (13.7) (28.4) (35.7)
    Income taxes                                          (2.5)  (2.3)    6.4   12.8   14.4

                                                          ___________ ___________ _________
    Non GAAP net income/(loss) from discontinued
    operations                                              1.2    0.4  (7.3) (15.6) (21.3)

                                                          ___________ ___________ _________
    Amortization and asset impairments, net of taxes      (6.2)  (6.4)  (6.7)  (6.7) (26.0)
    Acquisition and Integration activities , net of taxes (2.4)  (2.5)  (0.7)  (1.9)  (7.5)
    Legal and litigation costs, net of taxes                  -  (2.2)  (1.5)  (1.8)  (5.5)

                                                          ___________ ___________ _________
    US GAAP net loss from discontinued operations         (7.4) (10.7) (16.2) (26.0) (60.3)

                                                          ___________ ___________ _________


Unaudited US GAAP to Non GAAP reconciliation for the nine months to September 30, 2013 recast for DERMAGRAFT as a discontinued operation

                                                     US GAAP
                                                     Reported            Adjustments


                                                                  (a)    (b)    (c)   (d)
                                                           $M      $M     $M     $M    $M
    Product sales                                     3,477.1       -      -      -     -
    Royalties                                           112.4       -      -      -     -
    Other revenues                                       18.8       -      -      -     -
    Total revenues                                    3,608.3       -      -      -     -

    Costs and expenses:

    Cost of product sales                               492.2       -      -      -     -
    R&D                                                 703.3  (19.9)      -      -     -
    SG&A                                              1,198.0 (106.5)      -      - (8.1)
    Goodwill impairment charge                            7.1   (7.1)      -      -     -
    Gain on sale of product rights                     (14.6)       -      -   14.6     -
    Reorganization costs                                 47.2       -      - (47.2)     -
    Integration and acquisition costs                    39.9       - (39.9)      -     -
    Depreciation                                            -       -      -      -     -
    Total operating expenses                          2,473.1 (133.5) (39.9) (32.6) (8.1)

    Operating income                                  1,135.2   133.5   39.9   32.6   8.1

    Interest income                                       1.6       -      -      -     -
    Interest expense                                   (27.5)       -      -      -     -
    Other expense, net                                  (1.6)       -      -      -     -
    Total other (expense)/income, net                  (27.5)       -      -      -     -

    Income/(loss) from continuing operations before
    income taxes and equity in earnings of equity
    method investees                                  1,107.7   133.5   39.9   32.6   8.1

    Income taxes                                      (235.3)  (32.4)  (3.1)  (9.4) (3.1)

    Equity in earnings of equity method investees,
    net of tax                                            0.6       -      -      -     -

    Income/(loss) from continuing operations            873.0   101.1   36.8   23.2   5.0
    Loss from discontinued operations                 (271.9)       -      -  271.9     -

    Net income/(loss)                                   601.1   101.1   36.8  295.1   5.0

    Impact of convertible debt, net of tax               22.7       -      -      -     -

    Numerator for diluted EPS                           623.8   101.1   36.8  295.1   5.0

    Weighted average number of shares (millions) -
    diluted                                             587.5       -      -      -     -

    Diluted earnings per ADS                           318.6c   51.6c  18.8c 150.6c  2.5c

    (table continued)

                                                     Non GAAP
                                                     Reported                   Memo
                                                                              Non GAAP
                                                                             including
                                                                            DERMAGRAFT
                                                                            operations
                                                                       DERMAGRAFT
                                                                       operations   Total
                                                       (e)
                                                        $M       $M            $M      $M
    Product sales                                        -  3,477.1          64.7 3,541.8
    Royalties                                            -    112.4             -   112.4
    Other revenues                                       -     18.8             -    18.8
    Total revenues                                       -  3,608.3          64.7 3,673.0

    Costs and expenses:

    Cost of product sales                           (26.5)    465.7          34.2   499.9
    R&D                                              15.2)    668.2          10.1   678.3
    SG&A                                            (47.6)  1,035.8          98.2 1,134.0
    Goodwill impairment charge                           -        -             -       -
    Gain on sale of product rights                       -        -             -       -
    Reorganization costs                                 -        -             -       -
    Integration and acquisition costs                    -        -             -       -
    Depreciation                                      89.3     89.3           4.0    93.3
    Total operating expenses                             -  2,259.0         146.5 2,405.5

    Operating income                                     -  1,349.3        (81.8) 1,267.5

    Interest income                                      -      1.6             -     1.6
    Interest expense                                     -   (27.5)           0.5  (27.0)
    Other expense, net                                   -    (1.6)         (0.3)   (1.9)
    Total other (expense)/income, net                    -   (27.5)           0.2  (27.3)

    Income/(loss) from continuing operations before
    income taxes and equity in earnings of equity
    method investees                                     -  1,321.8        (81.6) 1,240.2

    Income taxes                                         -  (283.3)          33.5 (249.8)

    Equity in earnings of equity method investees,
    net of tax                                           -      0.6             -     0.6

    Income/(loss) from continuing operations             -  1,039.1        (48.1)   991.0
    Loss from discontinued operations                    -        -             -       -

    Net income/(loss)                                    -  1,039.1        (48.1)   991.0

    Impact of convertible debt, net of tax               -     22.7             -    22.7

    Numerator for diluted EPS                            -  1,061.8        (48.1) 1,013.7

    Weighted average number of shares (millions) -
    diluted                                              -    587.5             -   587.5

    Diluted earnings per ADS                             -   542.1c       (24.6c)  517.5c

      The following items are included in Adjustments:     (a) Amortization and asset impairments: Impairment of IPR&D intangible assets acquired with Movetis ($19.9     million), impairment of goodwill relating to Shire's Regenerative Medicine Business ($7.1 million), amortization     of intangible assets relating to intellectual property rights acquired ($106.5 million), and tax effect of     adjustments;     (b) Acquisitions and integration activities: Costs primarily associated with acquisition of SARcode, Lotus and     Premacure ($11.5 million), charges related to the change in fair value of contingent consideration ($28.4     million), and tax effect of adjustments;     (c) Re-measurement of DAYTRANA contingent consideration to higher fair value ($14.6 million), costs relating to     the "One Shire" reorganization announced at Q1 2013 and the collective dismissal and closure of Shire's facility     at Turnhout, Belgium ($47.2 million), tax effect of adjustments and loss from discontinued operations, net of tax     ($271.9m);     (d) Legal and litigation costs: Costs related to litigation, government investigations, other disputes and     external legal costs ($8.1 million), and tax effect of adjustments; and     (e) Depreciation reclassification: Depreciation of $89.3 million included in Cost of product sales, R&D costs and     SG&A costs for US GAAP separately disclosed for the presentation of Non GAAP earnings.

Unaudited US GAAP to Non GAAP reconciliation for full year 2012 recast for DERMAGRAFT as a discontinued operation

                                                     US GAAP
                                                     Reported            Adjustments


                                                                  (a)    (b)    (c)   (d)
                                                           $M      $M     $M     $M     $M
    Product sales                                     4,252.9       -      -      -      -
    Royalties                                           241.6       -      -      -      -
    Other revenues                                       32.9       -      -      -      -
    Total revenues                                    4,527.4       -      -      -      -

    Costs and expenses:

    Cost of product sales                               585.8       -      -      -      -
    R&D                                                 953.0  (71.2) (23.0)      -      -
    SG&A                                              1,948.0 (280.3)      -      - (94.1)
    Goodwill impairment charge                              -       -      -      -      -
    Gain on sale of product rights                     (18.1)       -      -   18.1      -
    Reorganization costs                                    -       -      -      -      -
    Integration and acquisition costs                    13.5       - (13.5)      -      -
    Depreciation                                            -       -      -      -      -
    Total operating expenses                          3,482.2 (351.5) (36.5)   18.1 (94.1)

    Operating income                                  1,045.2   351.5   36.5 (18.1)   94.1

    Interest income                                       3.0       -      -      -      -
    Interest expense                                   (38.2)       -      -      -      -
    Other expense, net                                  (2.2)     4.0      -      -      -
    Total other income/(expense), net                  (37.4)     4.0      -      -      -

    Income/(loss) from continuing operations before
    income taxes and equity in earnings of equity
    method investees                                  1,007.8   355.5   36.5 (18.1)   94.1

    Income taxes                                      (203.1)  (45.0)  (5.7)      - (25.3)

    Equity in earnings of equity method investees,
    net of tax                                            1.0       -      -      -      -

    Income/(loss) from continuing operations            805.7   310.5   30.8 (18.1)   68.8
    Loss from discontinued operations                  (60.3)       -      -   60.3      -

    Net income/(loss)                                   745.4   310.5   30.8   42.2   68.8

    Impact of convertible debt, net of tax               31.3       -      -      -      -

    Numerator for diluted EPS                           776.7   310.5   30.8   42.2   68.8

    Weighted average number of shares (millions) -
    diluted                                             593.5       -      -      -      -

    Diluted earnings per ADS                           392.7c  156.7c  15.5c  21.3c  34.8c

    (table continued)

                                                     Non GAAP
                                                     Reported                   Memo
                                                                              Non GAAP
                                                                             including
                                                                            DERMAGRAFT
                                                                            operations
                                                                       DERMAGRAFT
                                                                       operations   Total
                                                          (e)
                                                           $M       $M            $M     $M
    Product sales                                           -  4,252.9        153.8 4,406.7
    Royalties                                               -    241.6            -   241.6
    Other revenues                                          -     32.9            -    32.9
    Total revenues                                          -  4,527.4        153.8 4,681.2

    Costs and expenses:

    Cost of product sales                              (29.0)    556.8         57.1   613.9
    R&D                                                (22.5)    836.3         12.5   848.8
    SG&A                                               (57.5)  1,516.1        114.7 1,630.8
    Goodwill impairment charge                              -        -            -       -
    Gain on sale of product rights                          -        -            -       -
    Reorganization costs                                    -        -            -       -
    Integration and acquisition costs                       -        -            -       -
    Depreciation                                        109.0    109.0          4.8   113.8
    Total operating expenses                                -  3,018.2        189.1 3,207.3

    Operating income                                        -  1,509.2       (35.3) 1,473.9

    Interest income                                         -      3.0          0.1     3.1
    Interest expense                                        -   (38.2)            -  (38.2)
    Other expense, net                                      -      1.8        (0.5)     1.3
    Total other income/(expense), net                       -   (33.4)        (0.4)  (33.8)

    Income/(loss) from continuing operations before
    income taxes and equity in earnings of equity
    method investees                                        -  1,475.8       (35.7) 1,440.1

    Income taxes                                            -  (279.1)         14.4 (264.7)

    Equity in earnings of equity method investees,
    net of tax                                              -      1.0            -     1.0

    Income/(loss) from continuing operations                -  1,197.7       (21.3) 1,176.4
    Loss from discontinued operations                       -        -            -       -

    Net income/(loss)                                       -  1,197.7       (21.3) 1,176.4

    Impact of convertible debt, net of tax                  -     31.3            -    31.3

    Numerator for diluted EPS                               -  1,229.0       (21.3) 1,207.7

    Weighted average number of shares (millions) -
    diluted                                                 -    593.5            -   593.5

    Diluted earnings per ADS                                -   621.0c      (10.5c)  610.5c

      The following items are included in Adjustments:     (a) Amortization and asset impairments: Impairment of IPR&D intangible assets for RESOLOR in the EU ($71.2     million), impairment charges of intellectual property rights acquired for RESOLOR in the EU ($126.7 million),     amortization of intangible assets relating to intellectual property rights acquired ($153.6 million), impairment     of available for sale securities ($4.0 million), and tax effect of adjustments;     (b) Acquisitions and integration activities: Up-front payments made to Sangamo Biosciences Inc. and for the     acquisition of the US rights to prucalopride (marketed in certain countries in Europe as RESOLOR) ($23.0 million),     costs primarily associated with the acquisition of FerroKin ($4.3 million), charges related to the change in fair     value of deferred contingent consideration ($9.2 million), and tax effect of adjustments;     (c) Divestments, reorganizations and discontinued operations: Re-measurement of DAYTRANA contingent consideration     to fair value ($18.1 million), tax effect of adjustments and loss from discontinued operations, net of tax     ($60.3m);     (d) Legal and litigation costs: Costs related to litigation, government investigations, other disputes and     external legal costs ($94.1 million), and tax effect of adjustments; and     (e) Depreciation reclassification: Depreciation of $109.0 million included in Cost of product sales, R&D costs and     SG&A costs for US GAAP separately disclosed for the presentation of Non GAAP earnings.

NON GAAP MEASURES

This press release contains financial measures not prepared in accordance with US GAAP. These measures are referred to as "Non GAAP" measures and include: Non GAAP operating income; Non GAAP net income; Non GAAP diluted earnings per ADS; effectivetax rate on Non GAAP income before income taxes and earnings/(losses) of equity method investees ("effective tax rate on Non GAAP income"); Non GAAP cost of product sales; Non GAAP research and development; Non GAAP selling, general and administrative; Non GAAP other income/expense; Non GAAP cash generation; Non GAAP free cash flow and Non GAAP net cash/(debt). These Non GAAP measures exclude the effect of certain cash and non-cash items, that Shire's management believes are not related to the core performance of Shire's business.

This press release also reports Non GAAP Memo financial information - including DERMAGRAFT operations. Subsequent to December 31, 2013 Shire entered into an agreement to sell its DERMAGRAFT assets to Organogenesis. As a result, Shire's financial information prepared on the basis of US GAAP presents DERMAGRAFT operations as discontinued. Shire's management believes that the Non GAAP Memo financial information is useful to investors since it provides an understanding of what Shire's performance would have been had DERMAGRAFT not been disposed of, which permits investors to compare that performance against guidance previously issued by Shire to investors.

These Non GAAP financial measures are used by Shire's management to make operating decisions because they facilitate internal comparisons of Shire's performance to historical results and to competitors' results. Shire's Remuneration Committee uses certain key Non GAAP measures when assessing the performance and compensation of employees, including Shire's executive directors.

The Non GAAP measures are presented in this press release as Shire's management believe that they will provide investors with a means of evaluating, and an understanding of how Shire's management evaluates, Shire's performance and results on a comparable basis that is not otherwise apparent on a US GAAP basis, since many non-recurring, infrequent or non-cash items that Shire's management believe are not indicative of the core performance of the business may not be excluded when preparing financial measures under US GAAP.

These Non GAAP measures should not be considered in isolation from, as substitutes for, or superior to financial measures prepared in accordance with US GAAP.

Where applicable the following items, including their tax effect, have been excluded when calculating Non GAAP earnings for both 2013 and 2012:

Amortization and asset impairments:

  • Intangible asset amortization and impairment charges; and
  • Other than temporary impairment of investments.

Acquisitions and integration activities:

  • Up-front payments and milestones in respect of in-licensed and acquired products;
  • Costs associated with acquisitions, including transaction costs, fair value adjustments on contingent consideration and acquired inventory;
  • Costs associated with the integration of companies; and
  • Noncontrolling interests in consolidated variable interest entities.

Divestments, reorganizations and discontinued operations:

  • Gains and losses on the sale of non-core assets;
  • Costs associated with restructuring and reorganization activities;
  • Termination costs; and
  • Income/(losses) from discontinued operations.

Legal and litigation costs:

  • Net legal costs related to the settlement of litigation, government investigations and other disputes (excluding internal legal team costs).

Depreciation, which is included in Cost of product sales, R&D and SG&A costs in our US GAAP results, has been separately disclosed for the presentation of 2013 and 2012 Non GAAP earnings.

A reconciliation of Non GAAP financial measures to the most directly comparable measure under US GAAP is presented on pages 9 to 10.


For further information please contact:

Investor Relations      
       
Eric Rojas    
[email protected]    
+1-781-482-0999

Sarah Elton-Farr    
[email protected]    
+44-1256-894157

Media      
Jessica Mann    
[email protected]    
+44-1256-894-280

Gwen Fisher    
[email protected]    
+1-484-595-9836

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Micron Technology, Inc., a global leader in advanced semiconductor systems, will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Micron’s broad portfolio of high-performance memory technologies – including DRAM, NAND and NOR Flash – is the basis for solid state drives, modules, multichip packages and other system solutions. Backed by more than 35 years of tech...
Contrary to mainstream media attention, the multiple possibilities of how consumer IoT will transform our everyday lives aren’t the only angle of this headline-gaining trend. There’s a huge opportunity for “industrial IoT” and “Smart Cities” to impact the world in the same capacity – especially during critical situations. For example, a community water dam that needs to release water can leverage embedded critical communications logic to alert the appropriate individuals, on the right device, as...
U.S. companies are desperately trying to recruit and hire skilled software engineers and developers, but there is simply not enough quality talent to go around. Tiempo Development is a nearshore software development company. Our headquarters are in AZ, but we are a pioneer and leader in outsourcing to Mexico, based on our three software development centers there. We have a proven process and we are experts at providing our customers with powerful solutions. We transform ideas into reality.
The web app is agile. The REST API is agile. The testing and planning are agile. But alas, data infrastructures certainly are not. Once an application matures, changing the shape or indexing scheme of data often forces at best a top down planning exercise and at worst includes schema changes that force downtime. The time has come for a new approach that fundamentally advances the agility of distributed data infrastructures. Come learn about a new solution to the problems faced by software organ...
SYS-CON Events announced today the Containers & Microservices Bootcamp, being held November 3-4, 2015, in conjunction with 17th Cloud Expo, @ThingsExpo, and @DevOpsSummit at the Santa Clara Convention Center in Santa Clara, CA. This is your chance to get started with the latest technology in the industry. Combined with real-world scenarios and use cases, the Containers and Microservices Bootcamp, led by Janakiram MSV, a Microsoft Regional Director, will include presentations as well as hands-on...
With the Apple Watch making its way onto wrists all over the world, it’s only a matter of time before it becomes a staple in the workplace. In fact, Forrester reported that 68 percent of technology and business decision-makers characterize wearables as a top priority for 2015. Recognizing their business value early on, FinancialForce.com was the first to bring ERP to wearables, helping streamline communication across front and back office functions. In his session at @ThingsExpo, Kevin Roberts...
While many app developers are comfortable building apps for the smartphone, there is a whole new world out there. In his session at @ThingsExpo, Narayan Sainaney, Co-founder and CTO of Mojio, will discuss how the business case for connected car apps is growing and, with open platform companies having already done the heavy lifting, there really is no barrier to entry.
As more intelligent IoT applications shift into gear, they’re merging into the ever-increasing traffic flow of the Internet. It won’t be long before we experience bottlenecks, as IoT traffic peaks during rush hours. Organizations that are unprepared will find themselves by the side of the road unable to cross back into the fast lane. As billions of new devices begin to communicate and exchange data – will your infrastructure be scalable enough to handle this new interconnected world?
WebRTC has had a real tough three or four years, and so have those working with it. Only a few short years ago, the development world were excited about WebRTC and proclaiming how awesome it was. You might have played with the technology a couple of years ago, only to find the extra infrastructure requirements were painful to implement and poorly documented. This probably left a bitter taste in your mouth, especially when things went wrong.
Skeuomorphism usually means retaining existing design cues in something new that doesn’t actually need them. However, the concept of skeuomorphism can be thought of as relating more broadly to applying existing patterns to new technologies that, in fact, cry out for new approaches. In his session at DevOps Summit, Gordon Haff, Senior Cloud Strategy Marketing and Evangelism Manager at Red Hat, discussed why containers should be paired with new architectural practices such as microservices rathe...
SYS-CON Events announced today that G2G3 will exhibit at SYS-CON's @DevOpsSummit Silicon Valley, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Based on a collective appreciation for user experience, design, and technology, G2G3 is uniquely qualified and motivated to redefine how organizations and people engage in an increasingly digital world.
Any Ops team trying to support a company in today’s cloud-connected world knows that a new way of thinking is required – one just as dramatic than the shift from Ops to DevOps. The diversity of modern operations requires teams to focus their impact on breadth vs. depth. In his session at DevOps Summit, Adam Serediuk, Director of Operations at xMatters, Inc., will discuss the strategic requirements of evolving from Ops to DevOps, and why modern Operations has begun leveraging the “NoOps” approa...
Too often with compelling new technologies market participants become overly enamored with that attractiveness of the technology and neglect underlying business drivers. This tendency, what some call the “newest shiny object syndrome,” is understandable given that virtually all of us are heavily engaged in technology. But it is also mistaken. Without concrete business cases driving its deployment, IoT, like many other technologies before it, will fade into obscurity.
Organizations from small to large are increasingly adopting cloud solutions to deliver essential business services at a much lower cost. According to cyber security experts, the frequency and severity of cyber-attacks are on the rise, causing alarm to businesses and customers across a variety of industries. To defend against exploits like these, a company must adopt a comprehensive security defense strategy that is designed for their business. In 2015, organizations such as United Airlines, Sony...
The Internet of Things is in the early stages of mainstream deployment but it promises to unlock value and rapidly transform how organizations manage, operationalize, and monetize their assets. IoT is a complex structure of hardware, sensors, applications, analytics and devices that need to be able to communicate geographically and across all functions. Once the data is collected from numerous endpoints, the challenge then becomes converting it into actionable insight.